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Down-regulation of SMS1 and SMS2 with siRNA
The siRNA for human SMS1 targeted the sequence CACAC-TATGGCCAATCAGCAA (16) and the one for SMS2 targeted the sequence ACCGTCATGATCACAGTTGTA (23) . In preliminary experiments, the effects on SMSs RNA expression, SMS activity, and cell viability of the AllStars Negative Control siRNA (Qiagen) were compared with those of the transfection reagent by itself, and no difference was found; therefore, the Allstars Negative Control was used in subsequent experimentation as baseline. K562 were transfected with siRNAs by electroporation using the Amaxa Nucleofector device (Amaxa) according to the manufacturer's instructions. The protocol was optimized regarding the concentration of SMS1 siRNA, transfection, and post-transfection conditions in preliminary dose-response experiments (1-10 g SMS1 siRNA). Consequently, the following optimal conditions were used. Cells (1 × 10 6 K562 cells or 2 × 10 6 HL-60 cells) were transfected with 2-5 g of siRNA. After 30 min of incubation at 37°C, 5% CO 2 in 500 l of complete growth medium, cells were initially seeded at 0.5 × 10 6 cells/ml and subsequently diluted 1:4 once control cells reached a concentration 1.3 × 10 6 cells/ml. At the indicated time points after transfection, cells were washed twice with ice-cold PBS and processed according to the required analysis.
RNA isolation and reverse transcription for real-time PCR
To analyze the expression of SMS1 or SMS2 in U937, HL-60/ neo, HL-60/Bcr-abl, and K562 cells, total RNA was fi rst isolated from 1 × 10 6 cells using the RNeasy Mini Kit according to the manufacturer's protocol, including optional DNase digestion (Qiagen, Gmbh, Hilden, Germany). Further DNase digestion distribution of SMS activity, Sms1 localizes at the Golgi, whereas Sms2 localizes at the Golgi and plasma membrane (14, (16) (17) (18) . Modulation of Sms1 or Sms2 activity in most tested cell types has resulted in an alteration of ceramide levels, whereas changes in DAG mass have been elusive (16, (19) (20) (21) (22) (23) . On the other hand, in Hela cells it has been shown that, in spite of the absence of signifi cant changes of total DAG levels upon modulation of SMSs, intracellular DAG pools (in particular at the Golgi) appeared to be altered (16) .
Whereas inhibition of Sms1 by direct caspase cleavage has been shown after treatment with Fas ligand in Jurkat cells (24) , no molecular factors that are able to stimulate Sms1 or Sms2 expression or activity have been identifi ed. One of the conditions in which total SMS activity was found to be increased was a pool of samples isolated from patients with acute lymphoblastic leukemia, acute myeloid leukemia, and chronic myelogenous leukemia (CML) (25) .
CML is a myeloproliferative disorder of hemopoietic stem cells and occurs in 1 to 1.5 per 100,000, accounting for 15-20% of adult leukemia. CML is directly linked to a chromosomal abnormality caused by the reciprocal translocation of chromosomes 9 and 22, resulting in a shortened chromosome 22 termed the Philadelphia chromosome. This chromosomal translocation generates a fusion product between the breakpoint cluster region ( Bcr ) and the Abelson kinase ( Abl ) genes (26) (27) (28) (29) . The chimera now encodes for a constitutively active tyrosine kinase, Bcrabl, which initiates the leukemic transformation (30, 31) . In the clinical setting, CML is identifi ed by three distinct phases: a chronic phase, an accelerated phase, and a blast phase (32) . The chronic phase is characterized by a slight increase of granulocytic progenitors and a substantial increase of granulocytes in the peripheral blood. At this stage, pharmacological inhibition of the Bcr-abl tyrosine kinase activity by imatinib mesylate has proven key for the containment of the disease (33) (34) (35) . Nevertheless, the insurgence of mechanisms of resistance to current therapy, most commonly mutations in the ATP-binding pocket of Bcr-abl after long-term treatment with tyrosine kinase inhibitors, are causing disease progression from the chronic phase to the terminal blast phase (36) . The blast phase is characterized by a block of differentiation resulting in 30% or more myeloid or lymphoid blast cells in the peripheral blood or bone marrow, from where the blast cells eventually infi ltrate other organs such as spleen, liver, or lymph nodes (29) . These blast cells are refractory to current treatments, and the survival time for patients affected by blast crisis CML is 3 to 6 months (37) (38) (39) .
In this study, we provide evidence of a link between the expression of the BCR-ABL oncogene, its activity, and elevated SMS activity. We show that elevated expression of SMS1 and not SMS2 is responsible for the elevated SMS activity and that elevated Sms1 is important for sustaining proliferation of Bcr-abl-positive cells. Inhibition of Bcr-abl, SMS activity, or SMS1 expression results in an alteration of the ceramide to DAG ratio consistent with a negative effect on cell proliferation. Together, these results establish after transfection, cells were diluted to 0.2 × 10 6 cells/ml in complete medium, and 36 h after transfection, cells were harvested, washed twice with ice-cold PBS, and processed for lipid analysis. Effective down-regulation of Bcr-abl was determined by Western blotting, and an approximately 70% reduction of Bcr-abl in BCR-ABL siRNA treated cells was observed (data not shown).
SMS activity assay
SMS activity was performed as previously described with a few modifi cations (16) . Briefl y, three to four million cells were harvested on ice, washed in PBS, and resuspended in 150 l of homogenization buffer containing 250 mM Tris, 50 mM EDTA (pH 7.4), Pierce Halt phosphatase inhibitor, Pierce Halt protease inhibitor (Pierce, Rockville, IL), and 5 mM PMSF. Cells were then lysed by sonication at 11% power for 20 s (preliminary optimization experiments showed 95% cell lysis with these conditions). Unbroken cells were pelleted by centrifugation at 400 g for 5 min at 4°C, and the supernatant was collected and assayed for protein concentration using the Bio-Rad protein determination assay reagent (Bio-Rad, Hercules, CA). Fifty micrograms of proteins were used for SMS activity, which was carried out and analyzed as previously described (16) .
Total membrane preparation and Sms1 Western blotting
Twenty million cells were harvested on ice, washed in PBS, and resuspended in 800 l of homogenization buffer containing 250 mM Tris, 50 mM EDTA (pH 7.4), Pierce Halt phosphatase inhibitor, Pierce Halt protease inhibitor (Pierce), and 5 mM PMSF. Cells were then lysed as indicated for SMS activity and centrifuged at 1,000 g for 10 min at 4°C. Supernatants were collected and centrifuged at 120,000 g for 1 h at 4°C. Membrane pellets were resuspended in 200 l of homogenization buffer and passed through a 21 gauge needle until uniform. Membrane protein concentration was determined using the Bio-rad protein determination assay reagent (Bio-rad). Membranes were diluted with 4× sample buffer and incubated at 37°C for 30 min. Cell membrane proteins (80 g) were separated by 10% SDS-PAGE under reducing conditions and transferred to nitrocellulose membranes. Membranes were blocked with 5% milk PBS-Tween 0.1% for 1 h at room temperature. Membranes were then incubated with Sms1 antibodies raised against the full-length protein (1:1,000) (Ex-␣ Biologics, Maynard, MA) for 4 h at room temperature in 5% milk PBS-Tween 0.1%. After extensive washings, membranes were incubated with peroxidase-conjugated goatanti-rabbit (1:3,500; Santa Cruz Biotechnology) in 5% milk PBSTween 0.1% for 1 h at room temperature. Signals were visualized using Super Signal (Pierce Chemical Co.) and exposure to Kodak BioMax MR Film (Eastman Kodak Co., Rochester, NY).
Detection of poly(ADP-ribose) polymerase cleavage as an indicator of apoptosis
Analysis of poly(ADP-ribose) polymerase (PARP) cleavage was conducted on total lysates (20 g) on a 7.5% SDS-PAGE under reducing conditions. After transfer to nitrocellulose membranes and blocking as indicated above, PARP and its cleaved fragment were visualized using primary rabbit polyclonal antibodies (1:1,500; Santa Cruz Biotechnology) and secondary peroxidaseconjugated goat-anti-rabbit (1:10,000; Santa Cruz) both in 5% milk PBS-Tween 0.1%. Signals were visualized using ECL (GE Healthcare) and exposure to Kodak BioMax MR Film (Eastman Kodak Co.).
Lipid analysis
Ceramide, DAG, and SM species were measured by the Lipidomics Core Facility at MUSC (http://www.musc.edu/BCMB/ lipidomics/index.shtml). For the lipid measurements, 1 × 10 6 was performed using the Turbo DNA free kit according to the manufacturer's protocol (Applied Biosystems). The fi rst strand cDNA synthesis was prepared from 1 g of RNA using Superscript III (Invitrogen) according to the manufacturer's recommendations. Real-time PCR amplifi cation was carried out as described by Villani et al. (16) .
Lentiviral-mediated down-regulation of SMS1
For lenti-viral experiments, K562 cells were transduced with nontargeting control particles ( shRNA-NTCP ) or Mission lentiviral transduction particles (both from Sigma-Aldrich) that contained the pLKO.1-puro vector including the SMS1 targeting sequence 5 ′ -CCGGCCAACTGCGAAGAATAATGAACTCGAGTT CATTATTCTTCGCAGTTGGTTTTTTG-3 ′ ( sh-RNA-SMS1 ). During transduction, 3 × 10 4 K562 cells/ml resuspended in RPMI-1640 containing 10% FBS and 10 g/ml of Hexabromide (Sigma) were infected at a multiplicity of infection of 10 with the appropriate lentiviral particles. Cells were incubated at 37°C, 5% CO 2 , and 3 days after transduction 10 g/ml of puromycin (Sigma) was added to the media to select for pLK0.1-puro positive clones and re-added every 3-4 days to maintain selection. The concentration of puromycin needed to select for vector expressing clones was based on a kill-curve analysis showing 70-80% cell death after 3 days in nontransduced K562 cells (data not shown). K562 cells in each of the experimental groups (as above) and incubated for 4 h at 37°C and 5% CO 2 . After incubation, cells were centrifuged at 1,000 g for 5 min at 4°C, and the supernatant was removed. The cell pellets were washed twice with ice-cold PBS to remove all excess unincorporated [ 3 H]thymidine followed by a 30 min incubation in 5% ice-cold trichloroacetic acid (700 l). The suspensions were centrifuged as above, trichloroacetic acid was removed, and pellets were subsequently solubilized in 0.5 N NaOH containing 0.5% SDS (500 l). For analysis, 150 l of the solubilized pellets were counted in 4 ml of scintillation fl uid (MP Biomedicals), and incorporated [ 3 H]thymidine was measured as counts per minute in a Beckman-Coulter scintillation counter. CPM values were normalized to the total 500 l of solubilized pellets. the expression of SMS1 and SMS2 was determined by real-time PCR. The expression of SMS1 mRNA in K562 and HL-60/bcr-abl was signifi cantly higher than that in Bcr-abl-negative cells (HL-60/neo or U937) ( Fig. 2A ) . The results obtained by real-time PCR were also confi rmed by Northern blot analysis of total RNA collected from HL-60/neo and HL-60/bcr-abl cells, using the fulllength SMS1 cDNA as probe (data not shown). On the other hand, the expression of Bcr-abl caused a reproducible and signifi cant drop of SMS2 mRNA level ( Fig. 2A ) . The absolute expression level of SMS2 in HL-60/neo is signifi cantly lower than that of SMS1 (1.32 × 10 Ϫ 3 vs. 6.24 × 10 Ϫ 4 MNE), and, by dropping in Bcr-abl-positive cells, it became minimal.
Down-regulation of BCR-ABL
K562 cells or 2 × 10 6 HL-60/neo or HL-60/Bcr-abl cells were used for each experimental condition. Aliquots of lipid extracts were used to measure inorganic phosphate, which was used as normalization factor (42) .
Statistical analysis
Statistical analysis of the data was performed using Student's t -test, and P < 0.05 was considered statistically signifi cant.
RESULTS

Expression of Bcr-abl increased SMS activity
It has been shown that a pool of mononuclear cells isolated from peripheral blood or bone marrow of chemoresistant patients with different leukemias presented elevated SMS activity along with decreased ceramide levels (25) . Therefore, to assess if increased SMS activity was associated with specifi c hematological malignancies, a screening was carried out in different leukemic cell lines in vitro. K562 cells exhibited a signifi cantly higher SMS activity (by approximately 10-fold) compared with the other cell lines ( Fig. 1A ) . The enzymatic activity of SMS was linear with the amount of cell lysates and time of reaction (data not shown), indicating that the differences were not an artifact of the assay conditions. K562 cells originate from a pleural effusion of a patient with chronic myelogenous leukemia (CML) in blast crisis and are characterized by the expression of the BCR-ABL oncogene.
To determine if the increase of SMS in K562 was a direct result of BCR-ABL expression, SMS activity was measured in HL-60 cells stably transfected with the BCR-ABL gene (HL-60/bcr-abl) and compared with cells transfected with the empty vector (HL-60/neo) (40) ( Fig. 1B ) . It was found that the expression of Bcr-abl in HL-60 cells induced a 9-fold increase of SMS activity but not due to the assay experimental conditions (data not shown). As a complementary approach, the effect of inhibition of Bcr-abl tyrosine kinase activity on SMS activity was determined in K562 cells. Inhibition of Bcr-abl activity by imatinib mesylate induced a dose-and time-dependent inhibition of SMS activity, which became signifi cant by 24 h of incubation and continued through 36 h of treatment (Fig. 1C) . The inhibition of SMS activity by imatinib at 24 h and 30 h was observed when no signifi cant effect of the drug on cell proliferation could be appreciated. Inhibition of cell proliferation by imatinib started at 36 h of treatment with all concentrations tested (supplementary Fig. I) , and it was accompanied by the presence of 3.7% of dead cells at 0.2 M, 8.3% at 0.4 M, and 10% at 1 M (vs. 2% of dead cells in the vehicle control sample). Together, these results suggest that, in K562 cells, SMS activity is regulated by the tyrosine kinase activity of Bcr-abl.
Bcr-abl-induced increase of SMS activity is attributable to the up-regulation of Sms1
Two SMSs have been identifi ed in mammalian cells. To determine which of these SMSs is responsible for the observed increase in SMS activity, the effect of Bcr-abl on Supplemental Material can be found at:
whereas they were able to detect Sms2 in Hela cells; data not shown. Together, these data suggest that Sms1 may indeed be responsible for the increase in SMS activity observed in Bcr-abl-positive cells.
To prove that Bcr-abl regulates SMS activity by promoting SMS1 expression and activity, SMS1 was down-regulated by transient treatment with siRNA in K562 cells. Downregulation was achieved by electroporation of SMS1 -specifi c siRNA followed by both expression and activity analysis at various time points. Down-regulation of SMS1 caused a signifi cant reduction of the expression of SMS1 after 24 h ( Fig. 3A ) , and the SMS1 down-regulation caused a 50-60% of total SMS activity ( Fig. 3B ) . The SMS1 siRNA showed target specifi city because no change of SMS2 expression was observed ( Fig. 3C ) . Similarly, treatment of K562 cells with a validated SMS2 siRNA (23) caused the already minimal SMS2 expression to become barely detectable (at 48 h after siRNA, SMS2 expression went from 5.1 × 10 Ϫ 6 ± 7.9 × 10 Ϫ 7 to 1.8 × 10 Ϫ 6 ± 1.9 × 10 Ϫ 7 MNE) while not affecting SMS1 expression (data not shown). In contrast to SMS1 , down-regulation of SMS2 did not affect SMS activity ( Fig. 3D ) . Together, these observations demonstrate that Sms1 is the main contributor to the Bcr-abl-induced increase of SMS activity.
To confi rm that increased expression of SMS1 in Bcrabl-positive cells led to elevated Sms1 protein, Western blotting was performed on the total membrane fraction isolated from Bcr-abl-negative and -positive cell lines. As shown in Fig. 2B and in line with the expression pattern ( Fig. 2A ) , the levels of Sms1 in Bcr-abl-negative cells were barely detectable, whereas they were signifi cantly elevated in bcr-abl-positive cells (K562 and HL-60/bcr-abl). The identifi cation of the Sms1 band in leukemia cells was based on the comparison with Hela cells treated with SMS1 siRNA ( Fig. 2C ) . On the other hand, no commercially available antibodies for Sms2 (ExAlpha or Santa Cruz) were able to detect any band in any of these cell lines, Total membrane fractions were collected from exponentially growing cells, and Western blotting analysis using 80 g of proteins was performed as described in the Materials and Methods section using nonpurifi ed polyclonal antibodies raised against recombinant full-length Sms1 protein (ExAlpha Biologicals). Equal loading was confi rmed by Ponceau staining (loading control panel). C: The identity of the Sms1 band was determined based on the specifi c disappearance of the same molecular weight band in Hela cells after siRNA-mediated SMS1 down-regulation as compared with cells transfected with a scrambled siRNA (CT siRNA) or a siRNA against SMS2 (SMS2 siRNA). These results are representative of two separate experiments. Where error bars are not visible, the error bar is too small compared with the scale of the y axis. Asterisk indicates signifi cance to HL-60/neo ( P < 0.05). MNE, mean of normalized expression. ( Fig. 4B ) . The overall lipid changes cause a shift of the ratio between total ceramide levels over total DAG levels from 0.11 of control cells to 0.45 of D609-treated cells at 24 h and from 0.09 of control cells to 0.50 of D609-treated cells at 48 h (supplementary Table I ). Similarly, although in a less pronounced manner, C18:0 and C22:1 ceramide levels accumulated after 48 h of down-regulation of SMS1 ( Fig. 4C ), whereas C14:0/C18:0 and C16:0/C18:0 DAG levels decreased signifi cantly after 24 h ( Fig. 4D ) . In this case, the ratio between total ceramide levels over total DAG levels goes from 0.17 of control cells to 0.26 of SMS1 cells after 24 h and from 0.46 to 0.64 after 48 h (supplementary Table II ) .
Together, these results indicate that inhibition of SMS/ Sms1 induced changes in some ceramide and DAG molecular species that shift the ceramide/DAG ratio in favor of ceramide.
Modulation of Bcr-abl expression and activity caused lipid changes consistent with downstream regulation of Sms1
If Bcr-abl promotes SMS1 expression and activity, then modulation of Bcr-abl activity should cause lipid changes consistent with changes in SMS activity. To investigate this relationship, we fi rst determined the effect of Bcr-abl expression on basal levels of DAG, ceramide, and SM by mass
Inhibition of SMS activity caused accumulation of ceramide and a decrease of DAG
Because SMS promotes the formation of DAG by consuming ceramide and DAG sustains cell proliferation (whereas ceramide has generally a negative effect on cell growth) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) , lipid analysis upon modulation of SMS activity was conducted to determine its impact on the levels of these bioactive lipids. To this aim, lipid levels were determined upon inhibition of SMS activity by treatment with the SMS pharmacological inhibitor D609 (50 g/ml) ( Fig. 4A, B ) or siRNA-mediated down-regulation of SMS1 ( Fig. 4C, D) in K562 cells. Cells for each experimental condition were collected after 24 h and 48 h of treatment. Because the basal levels of the lipids (for these and all subsequent lipid measurements) were variable among separate experiments (whereas the pattern of changes for each experiment was similar as compared with other repeat experiments), results are reported as fold of time-matched controls. Absolute values of all detected ceramide, SM, and DAG molecular species for a representative experiment are provided in supplementary Tables I and II. Pharmacological inhibition of SMS induced a signifi cant accumulation of representative ceramide species C18:0 and C22:1 at 24 h and 48 h of treatment (Fig. 4A) . On the other hand, the levels of representative DAG species C14:0/C18:0 and C16:0/C18:0 signifi cantly decreased Supplemental Material can be found at: ( Fig. 6A, B and supplementary Table IV ). These changes resulted in an overall shift of the total ceramide over total DAG ratio from 0.34 of control cells to 1.34 of BCR-ABL down-regulated cells. Furthermore, Bcr-abl inhibition resulted in a signifi cant decrease of total SM levels because the levels of several molecular species were affected (supplementary Table 4C ).
The effect of loss of active Bcr-abl on DAG, ceramide, and SM levels was also determined in K562 cells after pharmacological inhibition with imatinib. K562 cells were treated with 0.4 M and 1 M imatinib for 24 h and 30 h (concentrations of imatinib and time of incubation that effectively inhibited SMS activity before affecting cell proliferation; supplementary Fig. 1 ) . Cells for each experimental condition were collected, and lipids were extracted for mass spectrometry analysis. Accumulation of the representative C18:0 and C22:1 ceramide species was observed after 24 h and in a more pronounced manner after 30 h of treatment with both concentrations ( Fig. 6C) . On the other hand, C14:0/C18:0 and C16:0/C18:0 DAG levels were greatly suppressed after 24 h of treatment with both imatinib concentrations, and they remained low after 30 h of incubation. In the presence of 1 M imatinib, the reported lipid changes cause a shift of the ratio between total ceramide over total DAG from 0.64 of control cells to 1.21 of imatinib-treated cells after 24 h and from 0.34 to 1.03 after 48 h. Absolute lipid values from one representative experiment are reported in supplementary Table 5 . Together, these results are consistent with modulation of SMS activity by Bcr-abl.
Inhibition of Sms1 caused a signifi cant defect in cell growth of Bcr-abl-positive cells
Because down-regulation of SMS1 caused a decrease of DAG and an increase of ceramide and because DAG and ceramide are involved in the regulation of cellular spectrometry. HL-60/neo and HL-60/Bcr-abl cells ( Fig. 5 ) were grown under standard conditions and collected once the cells reached the logarithmic phase of growth. Cells with similar passage numbers were used to control for lipid changes resulting from cell culture aging, potentially disguising the lipid changes specifi cally mediated by Bcr-abl expression. The levels of several DAG and SM species were increased in HL-60/Bcr-abl cells as compared with HL-60/neo ( Fig. 5  and supplementary Table III ). In particular, the representative DAG species that decreased upon down-regulation of SMS1 , C14:0/C16:0, and C16:0/C18:0 were also elevated in BCR-ABL -expressing cells ( Fig. 5A ) . Moreover, the majority of SM species were signifi cantly elevated in HL-60/Bcr-abl cells as compared with HL-60/neo ( Fig. 5B and supplementary Table IIIC ). This is in agreement with the enhanced SMS activity observed in HL-60/Bcr-abl cells as compared with HL-60/neo ( Fig. 1B ) . BCR-ABL expression did not decrease ceramide levels (supplementary Table IIIA ).
In a complementary approach, the effect of siRNAmediated down-regulation of BCR-ABL was determined on SMS-regulated lipids. The amount of siRNA, time of incubation, and cell culture conditions were optimized in preliminary experiments, and conditions were selected on the basis of maximum BCR-ABL down-regulation, as measured by Western blotting, and decreased SMS activity (data not shown). HL-60/bcr-abl cells were treated with siRNA targeting BCR-ABL (Bcr-abl Ϫ ) or with the scrambled siRNA Allstar control (SCR), and cells from each experimental condition were harvested 36 h after siRNA treatment for lipid analysis. Absolute lipid levels from one representative experiment are reported in supplementary Table IV , and representative lipid species are reported in Fig. 6 . These results showed that reduction of BCR-ABL expression induced a signifi cant increase of the levels of representative ceramide species C18:0 and C22:1 and a decrease of representative DAG species C14:0/C18:0 and C16:0/C18:0 activity in K562 [ Fig. 1A] ) . Thus, to investigate the biological effect of SMS1 in K562 cells and to obtain a more reproducible effect on cell proliferation, we aimed at achieving down-regulation of SMS1 that would approximate as much as possible the levels of bcr-abl-negative cells (HL-60 neo or U937 cells). To this aim, K562 cells were fi rst transduced with viral particles containing short hairpin RNA targeting SMS1 (shRNA-SMS1) followed by selection of stably expressing cells (this ensured a basal 50% reduction of SMS1 expression [supplementary Fig. II] ) . To further down-regulate Sms1, K562 cells stably transduced with shRNA-SMS1 were transfected with SMS1 siRNA (shRNA-SMS1/SMS1), and those transduced with control shRNA (shRNA-NTCP) were transiently transfected with Allstar Scrambled siRNA (shRNA-NTCP/SCR) (supplementary Fig. II ) . After double SMS1 down-regulation (shRNA-SMS1/SMS1), SMS1 was approximately one tenth of the expression in control shRNA-NTCP/SCR cells (90% down-regulation). Sustained inhibition of SMS1 in K562 cells (shRNA-SMS1/SMS1) resulted in reduced [ (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) , the effect of Sms1 inhibition was determined on these cellular processes. K562 cells were fi rst treated with D609, and its effect on cell proliferation was tested by incorporation of tritiated thymidine ( Fig. 7A ) . A signifi cant inhibitory effect of D609 was observed after 24 h, and it continued after 48 h and 72 h of incubation. Next, the effect of specific downregulation of SMS1 was determined. Initially, transient down-regulation of SMS1 with siRNA delivered variable results depending on the extent of SMS1 reduction (inhibition of cellular proliferation was only observed in the case of suppression of SMS1 by more than 75%). We reasoned that this might be due to the high basal SMS1 expression in these cells and to a possible threshold effect. Indeed, in K562 cells, the levels of SMS1 expression after SMS1 siR-NA-mediated knock down (equal approximately to one third of basal SMS1 expression [ Fig. 3A] and corresponding to approximately one third of SMS activity [ Fig. 3B ]) were still signifi cantly higher than those of bcr-abl-negative cells ( SMS1 expression in HL-60 is ‫ف‬ 1/35th of K562 cells [ Fig. 2A] , and SMS activity in HL-60 cells is ‫ف‬ 1/10 of SMS SMS activity has been associated with some transformed phenotypes (8, 11, 25) ; thus, the regulation of Sms1 by Bcr-abl reported herein represents the fi rst molecular link between a well-known oncogene and an SMS to support that association.
The involvement of Sms1 as a potential downstream target of Bcr-abl is unknown, and in general the role of ceramide in Bcr-abl-mediated signaling is unclear. In particular, whereas Bcr-abl expression was shown to impart total or partial resistance to treatment with exogenous short-chain ceramide analogs (C2 or C6 ceramide), Bcr-abl was also found to accelerate ceramide-mediated apoptosis by these same analogs (40, 54, 55) . Recently, accumulation of endogenous ceramide and a decrease of the antiapoptotic sphingolipid sphingosine 1 phosphate (S1P) were shown to be in part responsible for the cytotoxic effect exerted by imatinib treatment in CML-derived cell lines (56) . It was also shown that a shift of the balance between endogenous ceramide and S1P in favor of S1P might be of critical relevance for imparting imatinib resistance to CML cells (56, 57) . In our experimental model, we observed similar changes in ceramide levels after treatment with imatinib as those reported in the literature (56) , and these lipid changes were also observed in the case of pharmacological or siRNA-mediated inhibition of SMS1 . Together with the fact that inhibition of Bcr-abl causes a signifi cant block of SMS activity ( Fig. 1C ) , this suggests that, at least in part, ceramide accumulation upon inhibition of Bcr-abl might be due to inhibition of Sms1 activity. Down-regulation of SMS1 induced accumulation of specifi c ceramide molecular species such as C16:0, C18:0, C20:0, and C22:1, which were also accumulated upon pharmacological inhibition with D609 (supplementary  Tables IA and IIA) . D609 treatment also caused the accumulation of other ceramide species, and this may be due to the more rapid and sustained inhibition of SMS activity signifi cantly after 48 h and 72 h (Fig. 7B) . On the other hand, inhibition of SMS1 expression by more than 75% in HL-60/neo cells did not affect their cell growth (supplementary Fig. III ) . These results suggest that sustained inhibition of SMS1 expression/activity in K562 cells signifi cantly impairs cell proliferation.
On the other hand, down-regulation of SMS1 did not cause cytotoxicity or apoptosis. In fact, no signifi cant increase in trypan blue-positive cells and no positivity to propidium iodide were detected by fl uorescence-activated cell sorter analysis (data not shown). Moreover, no evidence of caspase-induced apoptosis was observed in K562 cells upon treatment with D609 or after down-regulation of SMS1 (supplementary Fig. IV and data not shown) . Together, these results implicate Sms1 in specifi c regulation of cell proliferation, and not cell death, of Bcr-Abl-positive cells.
DISCUSSION
In this study, we provide evidence of a link between the expression of the Bcr-abl oncogene, its activity, and elevated SMS activity. We further show that enhanced expression of SMS1 and not SMS2 is responsible for the elevated SMS activity and that elevated Sms1 is important for sustaining proliferation of Bcr-abl-positive cells. Moreover, modulation of Bcr-abl, SMS activity, or SMS1 expression results in a similar alteration of the ratio of the bioactive lipids ceramide and DAG. Finally, inhibition of SMS1 signifi cantly affects cell proliferation of Bcr-abl-positive cells, consistent with the shift of the ceramide to DAG ratio in favor of ceramide.
These results are signifi cant because no molecular factors that are able to stimulate Sms1 or Sms2 expression/ activity have been identifi ed. In particular, increased K562 cells. The difference in the requirement of SMS1 expression for proliferation between Bcr-abl-positive and -negative cells may be linked to the expression of SMS2 and the ability of Sms2 to compensate for the loss of Sms1. In fact, SMS2 is barely detectable in Bcr-abl-positive K562 but is expressed in HL-60 to a similar level as SMS1 ( Fig. 2A ) . This scenario implies that whenever Sms1 is the only SMS expressed in a certain cell type, then its activity is crucial for the survival of those cells.
An interesting observation is the fact that SMS1 mRNA is increased in Bcr-abl-positive cells, opening up the question of the mechanism by which SMS1 expression is stimulated by Bcr-abl (transcriptional regulation or mRNA stability). Preliminary results support the fi rst mechanism; thus, in the near future it is our intention to characterize the transcriptional regulation of SMS1 by Bcr-abl to elucidate the signaling pathway, down-stream of Bcr-abl, responsible for up-regulation of SMS1 .
Even if K562 cells are blast phase CML, and therefore characterized by a block of differentiation potentially due to the accumulation of mutations in addition to the formation of the Bcr-abl chimaera, Sms1 activity is still under the control of the Bcr-abl tyrosine kinase activity. Therefore, it is unlikely that Sms1 represents a "druggable" target to contain newly diagnosed blast-phase CML. On the other hand, in spite of the success obtained in controlling the chronic phase of CML, the increase in resistance to Bcrabl inhibitors is starting to represent a signifi cant medical challenge. Thus, establishing SMS1 as an important down-stream regulator of Bcr-abl may provide the basis for future work set to test Sms1 as a potential novel pharmacological target for CML, in particular for cases that arise from resistance to bcr-abl inhibitors.
In summary, the discovery of the Bcr-abl/Sms1 connection provides the fi rst molecularly characterized model for a better understanding of potential modes of regulation and downstream functions of the elusive Sms1. compared with siRNA and/or the activation of other ceramide-generating pathways, such as the de novo pathway (58) . C18:0, C20:0, and C22:1 ceramides were also increased upon pharmacological inhibition of Bcr-abl, and this is consistent with Sms1 being a downstream target of Bcr-abl. Also in the case of Bcr-abl inhibition, other ceramide species were increased, and this may be the result of activation of certain ceramide synthases, such as CerS1 (56) .
The fact that ceramide accumulation upon inhibition of Bcr-abl might be in part due to Sms1 inhibition is also supported by the analysis of SM and DAG levels. Indeed, we found that, upon inhibition of Bcr-abl or SMS/Sms1, there was a tendency for several species of SM to decrease, although some changes were not statistically signifi cant (supplementary Tables IC, IIC , and VC). Additionally, overexpression of Bcr-abl in HL-60 cells induced a significant accumulation of various species of SM (supplementary Table IIIC) , and siRNA-mediated down-regulation of the oncogene signifi cantly lowered SM levels (supplementary Table IVC) .
Inhibition of Bcr-abl or SMS/Sms1 induced a signifi cant drop of several DAG species, and these changes were even more pronounced than the changes in ceramide levels (supplementary Tables IB, IIB, and IIIB). Pharmacological and siRNA-mediated inhibition of SMS1 induced a signifi cant decrease of specifi c DAG molecular species, such as low abundant C14:0/C16:0 and C14:0/18:0 DAGs and highly represented C16:0/18:0, C16:0/18:1, C18:0/18:1, and Di-C16:0 DAGs. These same species were decreased upon inhibition of Bcr-abl (supplementary Table VB ), suggesting that there might be a specifi c pattern of DAG changes induced by modulation of SMS1. These results were also observed upon siRNA mediated down-regulation of BCR-ABL in HL-60/ bcr-abl cells (supplementary Table IVB ) .
The relationship between Bcr-abl and DAG has not been documented in the literature. Indirect evidence of the involvement of DAG as a downstream signaling molecule of Bcr-abl comes from reports showing that activation of phospholipase C (PLC) ␥ 1 and of the PI3K/Akt pathway is required for Bcr-abl signaling through mTOR/ p70S6-kinase (59, 60) . The regulation of mTOR/p70S6-kinase by PLC ␥ 1 seems to occur via modulation of calcium signaling (CaMKII) (presumably through formation of IP 3 ) and classical and novel protein kinase C (likely through production of DAG). In our system, we observed a very signifi cant drop of DAG levels when Bcr-abl or SMS/Sms1 was inhibited. Being Sms1 regulated by Bcr-abl, it is possible that part of the observed drop of DAG levels after inhibition of Bcr-abl is due to the decrease of SMS/Sms1 activity, in addition to inhibition of PLC ␥ 1.
The changes of ceramide (accumulation) and DAG (decrease) levels observed upon inhibition of Bcr-abl or SMS/Sms1 are consistent with the inhibition of cell proliferation observed in response to these treatments, and these concomitant lipid changes may work in concert to cause this phenotype. Down-regulation of SMS1 did not cause a change in proliferation of the Bcr-abl-negative cell line HL-60 ( supplementary Fig. III Supplemental Material can be found at:
